TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06631586

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTP-101C
Description: MTP-101C composed of double-encapsulated freeze-dried healthy donor microbiota. The fecal microbiota is frozen in the presence of a lyoprotectant (trehalose), freeze-dried, and double encapsulated into hypromellose capsules (Lonza, Morristown, NJ). Each capsule contains ≥ 1 x 10 11 and ≤ 2.0 x 10 11 bacterial cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTP-101S
Description: MTP-101S contains identical healthy donor microbiota double encapsulated in VCaps Plus (Lonza). These capsules are also composed of hypromellose but disintegrate in the proximal small bowel. Each capsule contains ≥ 1 x 10 11 and ≤ 2.0 x 10 11 bacterial cells.
Study: NCT05858918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with clopidogrel 75 mg PO daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with ticagrelor 90 mg PO twice daily
Study: NCT06632977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic testing
Description: undergo genetic testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic testing
Description: undergo genetic testing
Study: NCT00749827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypotonic hydration
Description: Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours.
Study: NCT06632977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic testing
Description: undergo genetic testing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valemetostat Tosylate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: undergo Magnetic Resonance Imaging
Study: NCT05187728

Intervention type: OTHER
Intervention: No Intervention
Description: No more intervention will be given.

Intervention type: OTHER
Intervention: No Intervention
Description: No more intervention will be given.
Study: NCT06632977

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: undergo Magnetic Resonance Imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: undergo Magnetic Resonance Imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: undergo Computed Tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: undergo Computed Tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: undergo Computed Tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone scan
Description: undergo Bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone scan
Description: undergo Bone scan
Study: NCT06398379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Virome Transplantation
Description: The primary steps of the production of fecal virome transplantation capsules is the same as when producing fecal microbiota transplantation capsules. Through an subsequent proces of filtering bacterial parts of the material are removed. The material, now called fecal virome transplanation material, has then been moved to capsules and stored in -80c untill use.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota Transplantation
Description: Donor fecal material is mixed with cryoprotectant and NaCl. Following processing the material transfered to capsules and is stored at -80c prior to use.
Study: NCT05465551

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Stress Management Toolkit
Description: The toolkit will be a home-based, dyadic tangible toolkit comprised of simple tools to help people living with dementia (PLWD) and their care partners manage stress at home. Potential tools for the toolkit includes low burden, high safety tools such as weighted blankets, robotic pets and baby dolls, guided journals, aromatherapy and bright light therapy devices, and massage and acupressure tools. The tookit will also include user-safety guidelines and directions on how to use each tool. Tools will be included for participants with dementia and care partners.
Study: NCT01169792

Intervention type: DRUG
Intervention: tamoxifen
Study: NCT04304092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will exercise under supervision. Exercise dose will vary by amount and intensity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will exercise under supervision. Exercise dose will vary by amount and intensity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will exercise under supervision. Exercise dose will vary by amount and intensity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will exercise under supervision. Exercise dose will vary by amount and intensity
Study: NCT05375253

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Enriched Activated Natural Killer Cell Infusion
Description: αβ TCR/CD19 depleted (DEA-NK) cells on day +7 post T-cell replete Haplo-Tx with PTCY
Study: NCT05928312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib Combined With Chemotherapy
Description: 1.Security introduction period:~\[1\] Safety introduction period (N=6), fruquintinib combined with three-week regimen:~1. Fruquintinib: Three-week regimen of combined chemotherapy: 4mg/d, orally, once a day, taking the drug for 2 weeks and stopping the drug for 1 week, 3 weeks as a treatment cycle.~\[2\] Safety introduction period (N=6), fruquintinib combined 2-week regimen:~1. Fruquintinib: two-week combination chemotherapy regimen: 4mg/d, orally, once a day, taking the drug for 3 weeks and stopping the drug for 1 week, 4 weeks as a treatment cycle.~2. Dose expansion phase design(N=60) Cohort 1 (30 patients) : Fruquintinib combined with oxaliplatin. Cohort 2 (30 patients) : Fruquintinib combined with irinotecan .
Study: NCT05751343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE-HACI, plus atezolizumab-bevacizumab
Description: transartery chemoembolization and artery infusion of FOLFOX, simultaneously followed by intravenous atezolizumab plus bevacizumab
Study: NCT05664269

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: drink ingestion
Description: drink ingestion of a vanilla-flavoured beverage from a non-transparent shaker

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: drink ingestion
Description: drink ingestion of a vanilla-flavoured beverage from a non-transparent shaker

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: drink ingestion
Description: drink ingestion of a vanilla-flavoured beverage from a non-transparent shaker

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance-type exercise
Description: Lower body resistance-type exercise on the supine leg press and seated knee extension machine. Both machines 4 sets at 80% 1RM for 8-10 reps.
Study: NCT05851430

Intervention type: DEVICE
Intervention: PEF ablation
Description: Pulsed Electric Field (PEF) Ablation per institutional standard of care
Study: NCT06524310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation with low frequency rTMS at 1 Hz
Description: Stimulation with low-frequency rTMS at 1 Hz with 90% MT will be applied with a total of 180 pulses each time, which contained 18 trains with ten pulses and an interval of 20 s between any two adjacent trains. The TMS treatment course will be administered twice per week for 9 weeks; the first six treatments will be over the left DLPFC, the second six sessions will be over the right DLPFC, and the remaining six times will be placed on the bilateral DLPFC stimulation (64).
Study: NCT05664269

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: resistance-type exercise
Description: Lower body resistance-type exercise on the supine leg press and seated knee extension machine. Both machines 4 sets at 80% 1RM for 8-10 reps.
Study: NCT00003599

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E (AT)
Description: Orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Orally daily
Study: NCT05664269

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: resistance-type exercise
Description: Lower body resistance-type exercise on the supine leg press and seated knee extension machine. Both machines 4 sets at 80% 1RM for 8-10 reps.
Study: NCT06209840

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The session is 50 minutes long and consists of 20 minutes of classical physiotherapy for gross motor functions and 30 minutes of classical physiotherapy for the upper extremity. A total of 16 sessions will be applied 2 days a week for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study (Music) Group
Description: The session is 50 minutes long and consists of 20 minutes of classical physiotherapy for gross motor functions and 30 minutes of music therapy for the upper extremity. A total of 16 sessions will be applied 2 days a week for 8 weeks.
Study: NCT05659810

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin 300mg
Description: Preoperative gabapentin before spinal anesthesia
Study: NCT05201625

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: real time PCR
Description: real time PCR

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: real time PCR
Description: real time PCR

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: real time PCR
Description: real time PCR
Study: NCT04481555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Prophylactic azithromycin treatment 250 mg three times weekly vs placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Prophylactic azithromycin treatment 250 mg three times weekly vs placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICS
Description: All patients will receive LABA/LAMA medication. The ICS medication will be switched on/off according to the most recent blood eosinophil count (at inclusion + every 3 months) vs continued LABA/LAMA/ICS treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICS
Description: All patients will receive LABA/LAMA medication. The ICS medication will be switched on/off according to the most recent blood eosinophil count (at inclusion + every 3 months) vs continued LABA/LAMA/ICS treatment
Study: NCT05659810

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin 300mg
Description: Preoperative gabapentin before spinal anesthesia
Study: NCT06297174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racecadotril 100 mg Capsules
Description: Racecadotril 100 mg Capsules (test drug)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racecadotril 100 mg Capsules
Description: Racecadotril 100 mg Capsules (test drug)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIDRASEC®
Description: HIDRASEC® (reference drug)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HIDRASEC®
Description: HIDRASEC® (reference drug)
Study: NCT05517499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Randomized clinical trial
Study: NCT04924036

Intervention type: DRUG
Group type: OTHER
Intervention: glycopyrronium cloths
Description: Qbrexza is an anticholinergic indicated for topical treatment of axillary hyperhidrosis in adults and pediatric patients 9 years of age and older

Intervention type: DRUG
Group type: OTHER
Intervention: glycopyrronium cloths
Description: Qbrexza is an anticholinergic indicated for topical treatment of axillary hyperhidrosis in adults and pediatric patients 9 years of age and older

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo for this study are cloths that look like the qbrexza cloths but do not have any active ingredient.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo for this study are cloths that look like the qbrexza cloths but do not have any active ingredient.
Study: NCT05109663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKLB1028
Description: SKLB1028, capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKLB1028
Description: SKLB1028, capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKLB1028
Description: SKLB1028, capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKLB1028
Description: SKLB1028, capsule, oral
Study: NCT05735223

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maximal urethral length preservation technique of robot assisted radical prostatectomy (RALP).
Description: Stretched flaccid penile length (SFPL) was measured by a single male assessor at preoperative visit, and at the time of catheter removal (10 days post-surgery). The subjects were blinded to the measurements to prevent bias. Multiparametric MRI (MP-MRI) of the prostate were reviewed when available for surgical planning. All subjects underwent RALP with MULP using the technique previously published by Hamada et al. Continence defined as requiring no pads was assessed at 3 and 6 months postoperatively.
Study: NCT05845879

Intervention type: OTHER
Intervention: delivery
Description: delivery
Study: NCT05235334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MySOLIUS
Description: MySOLIUS is a portable light therapy device that is designed to deliver a small amount of targeted ultraviolet B (UVB) light to trigger the body's natural production of vitamin D.
Study: NCT06534918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Participants will be provided with a Fitbit. Self-reported physical activity, location, vital sign and sleep stage information will be collected and monitored every day for up to eight (8) weeks. Data will be synced to the My Wellness Research Software Platform, resulting in a weekly text or phone call check-in, based on participants preference.
Study: NCT06454877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active heating
Description: Preheating will be performed for 15 minutes 30 minutes before surgery with a hot air blowing device in accordance with the normothermia care package so that the body temperature is 36-37 C°.~Active heating during surgery will be done with a heating bed placed on the operating table.~Patients taken to the postoperative care unit will continue to be heated with a hot air blower and the device will be turned off when the body temperature reaches 37 C°.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pasive heating
Description: In accordance with the normothermia care package, the reflective blanket will be covered to cover the whole body 30 minutes before surgery.~During the operation, the body will be covered with a reflective blanket in accordance with the surgical intervention.~Patients taken to the postoperative care unit will continue to be warmed with reflective blankets.
Study: NCT06300268

Intervention type: DEVICE
Group type: OTHER
Intervention: AdvaPro Sirolimus Eluting Coronary Stent System
Description: Cardiac Stent
Study: NCT05238805

Intervention type: RADIATION
Group type: OTHER
Intervention: Observational heart and kidney on siemens TEP scan
Description: Same as arm description
Study: NCT06543329

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: polyglactin 910
Description: 75 PARTICIPANT, Vicryl suture was used in subcuticular suture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: poliglecaprone 25
Description: 75 PARTICIPANT, monocryl suture was used in subcuticular suture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: polypropylene
Description: 75 PARTICIPANT, Prolene suture was used in subcuticular suture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: polyester
Description: 75 PARTICIPANT, Polyester suture was used in subcuticular suture
Study: NCT06632977

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone scan
Description: undergo Bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG PET
Study: NCT04972019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Experimental Group
Description: Experimental training will occur in the home. The experimental training will last 8 weeks, each week having up to 4 sessions of therapeutic game play (based on tolerance). Each session will start with vitals and subjective pain level being measured and logged.~They will wear a computer system modified with biosensors, then do motor and cognitive baselines. Subsequently, participants will play an increasing number of games, targeted at cognitive domains of executive function (primary), memory and attention. At the end of every session vitals and subjective pain will be measured and logged.~Clinical Coordinator will call homes weekly to ascertain general health and issues with participation.~At the end of week 4 and 8 participants and their caregivers in the experimental group will fill a subjective evaluation questionnaire to gauge perceived benefits and technical difficulties when using the experimental system. Questions will be scored on a 5-point Likert scale.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Telerehabilitation Sham Control Group
Description: Sham control group will train playing web games while wearing a biosensor connected to a laptop provided, showing the web games. However biosensor data will not be used to control game difficulty.~Sham group controls will start every session with vitals and subjective pain levels being measured and logged. Then participants will play the same frequency and duration of sessions, however those will consist of web games training the same domains (memory, focusing, executive function). Interaction will be through a mouse, and data will be downloaded to a server maintained by the company doing the web games. Data will then be transferred to the research team.~At the end of every session vitals and subjective pain levels will again be measured and logged.~Once a week the Clinical Coordinator will call the home to ascertain general health and determine is there were issues with that week participation.
Study: NCT05798572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildosin group
Description: Patients in this group had flexible ureteroscopy (F-URS) with preoperative daily uptake of 8 mg silodosin for one week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placebo/control group
Description: included 70 patients for whom flexible ureteroscopy (F-URS) was done with daily preoperative intake of placebo tablets.
Study: NCT06632977

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET Scan
Description: Undergo PSMA PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET Scan
Description: Undergo PSMA PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET Scan
Description: Undergo PSMA PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: undergo blood collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: undergo blood collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: undergo blood collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 Vipivotide Tetraxetan
Description: Given IV
Study: NCT03443791

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Women Enrolled
Description: Diagnostic Testing will be performed. Results of individual test results will determine the degree of intervention offered.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Newborns of Female Study Participants
Description: Newborns will be tested after birth as soon as possible for CMV positivity.
Study: NCT06142409

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enzyme containing lozenge
Description: Lozenge containing multiple enzyme combination

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Enzyme containing lozenge
Description: Lozenge containing multiple enzyme combination
Study: NCT06752395

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transbronchial lung biopsy with radial probe endobronchial ultrasound (Cryobiopsy centered)
Description: When the lung nodule is visualized by bronchoscope using RP-EBUS, cryobiopsy is performed, followed by forceps biopsy.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transbronchial lung biopsy with radial probe endobronchial ultrasound (Forceps biopsy centered)
Description: When the lung nodule is visualized by bronchoscope using RP-EBUS, forceps biopsy is performed, followed by cryobiopsy.